BAYERI1 Stock Overview
Bayer S.A. (Peru) engages in the pharmaceuticals, consumer health, and crop science businesses in Peru.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BAYERI1 from our risk checks.
Bayer S.A. (Peru) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S/19.00 |
| 52 Week High | S/20.10 |
| 52 Week Low | S/14.50 |
| Beta | 0.10 |
| 1 Month Change | -5.47% |
| 3 Month Change | 34.75% |
| 1 Year Change | 34.75% |
| 3 Year Change | 34.75% |
| 5 Year Change | 35.71% |
| Change since IPO | 295.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAYERI1 | PE Pharmaceuticals | PE Market | |
|---|---|---|---|
| 7D | -5.5% | 2.0% | 0.4% |
| 1Y | 34.8% | -15.4% | 10.4% |
Price Volatility
| BAYERI1 volatility | |
|---|---|
| BAYERI1 Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in PE Market | 7.3% |
| 10% least volatile stocks in PE Market | 0.7% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | n/a | Heiko Klaus Mussmann | www.bayer.com/es/co/andina-ycac-home |
Bayer S.A. (Peru) engages in the pharmaceuticals, consumer health, and crop science businesses in Peru. It operates through three segments: Cropscience, Pharmaceutical, and Consumer Health. The Cropscience segment offers commercialized products, such as pesticides, fertilizers, seeds, and other general products for agricultural sector.
Bayer S.A. (Peru) Fundamentals Summary
| BAYERI1 fundamental statistics | |
|---|---|
| Market cap | S/279.75m |
| Earnings (TTM) | S/12.04m |
| Revenue (TTM) | S/337.51m |
23.2x
P/E Ratio0.8x
P/S RatioIs BAYERI1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYERI1 income statement (TTM) | |
|---|---|
| Revenue | S/337.51m |
| Cost of Revenue | S/237.03m |
| Gross Profit | S/100.48m |
| Other Expenses | S/88.44m |
| Earnings | S/12.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.82 |
| Gross Margin | 29.77% |
| Net Profit Margin | 3.57% |
| Debt/Equity Ratio | 0% |
How did BAYERI1 perform over the long term?
See historical performance and comparison